THE BLOOD clot controversy continues to stymie the rollout of the Oxford-AstraZeneca vaccine in Europe, despite no evidence to suggest causation over coincidence. Data published by the UK's drug regulator does show a number of side effects that can immediately follow the jab, however. ...
THE BLOOD clot controversy continues to stymie the rollout of the Oxford-AstraZeneca vaccine in Europe, despite no evidence to suggest causation over coincidence. Data published by the UK’s drug regulator does show a number of side effects that can immediately follow the jab, however.
